Grade III fetal bowel hyperechogenicity and/or loop dilatation observed at the second trimester of pregnancy can be due to several disease conditions, including cystic fibrosis (CF). Screening for frequent CF mutations is performed as a first step and, in certain situations, such as when a frequent CF mutation is found in the fetus, the increased risk of CF justifies an in-depth study of the second allele. To determine the contribution of large CFTR gene rearrangements in such cases, detected using a semiquantitative fluorescent multiplex PCR (QFM-PCR) assay, we collated data on 669 referrals related to suspicion of CF in fetuses from 1998 to 2009. Deletions were found in 5/70 cases in which QFM-PCR was applied, dele19, dele22_23, dele2_6b, dele14b_15 and dele6a_6b, of which the last three remain undescribed. In 3/5 cases, hyperechogenicity was associated with dilatation and/or gallbladder anomalies. Of the total cases of CF recognized in the subgroup of first-hand referrals, deletions represent 16.7% of CF alleles. Our study thus strengthens the need to consider large CFTR gene rearrangements in the diagnosis strategy of fetal bowel anomalies, in particular in the presence of multiple anomalies.
INTRODUCTION
Fetal hyperechogenic bowel is a relatively common event detected at the second-trimester ultrasound scan in 0.04-1.80% fetuses. 1, 2 It can be benign and transient, or an indicator of varied fetal pathologies including cystic fibrosis (CF) (MIM 219700), which has been reported in 2.5-10.0% of cases. [2] [3] [4] [5] [6] [7] CF is the most common severe autosomal recessive disorder in the Caucasian population with an overall incidence of approximately 1 in 3500 live births. [8] [9] [10] Although patients' life expectancy has greatly improved over past decades, CF remains a severe disease, allowing prenatal diagnosis when both parents are known carriers for CF mutations or when abnormal ultrasound signs are detected during pregnancy. It is now a European recommendation that mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene (OMIM*602421) should be investigated in fetuses with bowel anomalies such as hyperechogenic bowel and loop dilatation. 11 More than 1700 CFTR variations have been reported so far (http:// www.genet.sickkids.on.ca/cftr/). Most are point mutations, with variable distribution and frequency according to ethnic/geographic origin. 12 Large CFTR rearrangements such as deletions, insertions or duplications, which can be identified using semiquantitative assays, [13] [14] [15] account for 1-3% of CF mutations and 14-26% of unidentified alleles in CF patients. 13, 16, 17 To assess the frequency of large CFTR rearrangements in ultrasound signs suggestive of CF, data of 669 referrals related to suspicion of CF in fetuses were collated. In this study we report 5 cases out of 27 CF solved using a semiquantitative fluorescent multiplex PCR (QFM-PCR) assay.
SUBJECTS AND METHODS Subjects
A series of 669 cases referred from different French clinics were investigated from 1992 to October 2009 because of fetal bowel anomalies detected by routine ultrasound examination during the second or third trimester of pregnancy. Ultrasound signs were hyperechogenic bowel (sonographic density greater than that of the surrounding bone), intestinal loop dilatation, intraabdominal calcifications, meconium peritonitis and absence of gallbladder, with each sign being isolated or combined. According to French legislation, informed consent was obtained from the parents during a genetic counseling session. Data from amniotic fluid digestive enzyme (AF-DE) activities 18, 19 were collected, when available.
Samples from 450/669 couples were referred directly by clinicians to our laboratory (group 1, first-hand referrals). DNA samples from the other 219 couples were referred for further investigation after screening for frequent mutations in another laboratory (group 2).
CFTR gene analysis
Genomic DNAs were extracted from whole blood samples collected on EDTA or from amniotic fluid using varied protocols. DNA concentration and quality were determined for each sample.
Screening for point mutations
Different study levels were carried out, depending on the clinical context. 11 As a first step, screening for frequent mutations was performed using diverse commercial assays or, before 1998, using denaturing gradient gel electrophoresis (DGGE) 20, 21 focused on at least 10 exons. According to patients' ethnic/geographic origins, complementary screening for other mutations was carried out using DGGE or denaturing high-performance liquid chromatography (DHPLC). 22 In most cases no mutation was found and the couple was reassured. In cases in which one mutation was identified, complete scanning of the 27 CFTR coding regions and a search for large rearrangements was carried out to look for a second CF mutation.
Screening for and characterization of large CFTR rearrangements
We used the QFM-PCR assay developed and implemented in our laboratory in 2004, 13, 23 
RESULTS
In group 1 of first-hand referrals, 408/450 couples (91%) were tested for frequent mutations according to their geographic origin. Comprehensive CFTR gene studies were carried out in 42 cases, including a search for large rearrangements in 17 of them (Table 1) . CF was confirmed in 9 fetuses (2.0% of 450 fetuses), including 2 with a deletion (cases 1 and 4).
In group 2 of second-hand referrals composed of 219 couples, 101 cases were referred for complementary screening depending on geographic origin, 92 because one frequent mutation was identified, 10 because of suggestive ultrasound signs and 16 because of technical problems. Search for large rearrangements by QFM-PCR was undertaken in 53 cases (Table 1) . CF was confirmed in 18/219 cases (8.2%), including 3 with a large deletion (cases 2, 3 and 5).
Overall, of the 70 cases screened for gross rearrangements, a partial gene deletion was characterized in 5 cases (7.1%; Tables 2 and 3) . Large CFTR deletions represent in this study 11.1% (6/54) of alleles in the 27 CF fetuses: 16.7% (3/18) in the 9 CF fetuses of group 1 and 8.3% (3/36) in the 18 CF fetuses of group 2.
Case 1
First cousins of Turkish origin were referred for fetal hyperechogenic bowel at 20 weeks of gestation. 24 Screening for frequent mutations by the CF-OLA assay (PE Biosystems) was negative in both parents, whereas three peaks corresponding to exon 19 were missing in the fetus. The deletion was confirmed using real-time quantitative-PCR (TaqMan), in heterozygosity in the parents and homozygosity in the fetus. Given the late stage of gestation, the pregnancy was continued to term. The 10-year-old girl has classical CF with a positive sweat test (90 mEq/l).
Case 2
The couple was referred at 20 weeks because of fetal bowel hyperechogenicity and dilatation associated with nonvisualization of gallbladder. Screening for frequent mutations in another laboratory identified W1282X in the father and the fetus. Complementary analysis led to the identification of a new heterozygous 55 kb deletion in the mother and the fetus, encompassing exons 2-6b. An 11-bp sequence homology overlapped the inserted sequence and the 3¢ breakpoint. The genotype was compatible with classical CF and, given the persistence of ultrasound signs, the parents chose to terminate the pregnancy at 26 weeks.
Case 3
The couple was referred at 30 weeks for fetal ascites, hyperechogenic bowel wall with hypoechogenic loop content, which is indicative of incipient loop dilatation, and gallbladder sludge. The father and the fetus were found F508del heterozygous in another laboratory. Abnormally high AF-DE activities were compatible with ascites, probably caused by meconial peritonitis. We identified a heterozygous previously described deletion of exons 22 and 23 in the mother and the fetus. 14 Termination of pregnancy was performed and the diagnosis of CF confirmed by fetopathological examination. 
Case 4
The couple was referred at 25 weeks because of nonvisualization of fetal gallbladder associated with moderate digestive dilatation and hyperechogenicity. As screening for frequent mutations according to their geographic origin was negative in both parents, the study was stopped and the pregnancy carried out to term. However, neonatal screening for CF by determination of immunoreactive trypsinemia was positive in the baby, as was the sweat test (97 mEq/l). Complete analysis of the CFTR gene led to identification of the baby as compound heterozygous for the rare 2347delG mutation, inherited from the mother, and a paternal new large deletion removing exons 14b and 15 ( Figure 1 ).
Case 5
The couple was referred at 32 weeks because of fetal ascites and polyhydramnios. The father and the fetus were found F508del heterozygous in another laboratory. A novel deletion of exons 6a and 6b was identified by QFM-PCR in the mother and the fetus. Further characterization showed that it retains the first 12 codons of exon 6a, with a 7 bp homology at the breakpoints in exon 6a and intron 6b. Given the late stage of pregnancy, it was continued to term and the mother gave birth to a CF baby.
DISCUSSION
This is the first study reporting on the occurrence and frequency of large CFTR rearrangements in cases of bowel anomalies, hereby showing their notable contribution to the diagnosis of CF. The frequency of gross deletions among CF alleles found in affected fetuses (16.7% of first-hand referrals), which seems much higher than the 1.3% found in postnatally diagnosed CF patients in the same geographic population, 13 makes our QFM-PCR assay the method of choice for second-line screening after testing for frequent mutations, 11 the frequency of CFTR gross rearrangements could even be re-evaluated upwards in the next few years. We here refer to five large deletions, all of which could be detected using the MLPA assay, including three as yet undescribed: dele2_6b, dele6a_6b and dele14b_15.
As for other rearrangements described, 13, 16 these deletions seem to result from non-homologous recombination, with short sequence homologies at the breakpoints. Such deletions can result from slipped mispairing during DNA replication. 14 The 'super hotspot' CCAAR, described in 10/40 breakpoints of CFTR large rearrangements. 25 was however not found in any of the five deletions reported in our study. Although the consequences of the deletions have not been studied at the functional level, it is presumed that they truncate the CFTR protein and can thus be considered to have a severe effect. Identification of deletions and consecutive confirmation of the diagnosis of CF had implications for genetic counseling in the families, as it enabled prenatal diagnosis to be offered in further pregnancies as well as cascade testing in relatives.
The clinical presentations of these five cases were representative of the signs suggestive of CF in fetuses. 7 It is noteworthy that 3/5 CF fetuses carrying a deletion had associated digestive signs, all 3 with gallbladder anomalies. Few studies have been published about the association between CF and fetal gallbladder anomalies, 7, 26, 27 thus calling for larger studies to assess better the frequency of CF in fetuses with such anomalies.
The present cases also further illustrate the variety of patterns of AF-DE activities. As recently evidenced in a wide retrospective study, AF-DE could still be of value for prenatal diagnosis of CF, although after 20 weeks, a physiological low value may be impossible to distinguish from a pathological one. 28 In conclusion, our study strengthens the need to consider large CFTR gene rearrangements in the diagnosis strategy of fetal bowel anomalies, in particular in the presence of multiple anomalies.
